PtBio, a Japanese biotechnology company, is tackling global challenges to achieve a sustainable future by adopting bio-digital transformation (Bio-DX) and advanced genome editing. This article explores the strengths of both Bio-DX and genome editing in driving scientific and industrial advancements.
The Power of Bio-DX
Bio-DX is the result of collaborative research between Hiroshima University and PtBio. It is a comprehensive data analysis system that combines cutting-edge academic research with industrial applications. This bioinformatics tool enables advanced analysis by integrating genomes, genes, and pathways using the latest algorithms.
The successful development of Bio-DX is credited to PtBio’s high-precision sequencers, such as the PacBio Sequel IIe and Illumina NextSeq2000, and its team of highly skilled experts. By integrating various analytical methods—including Hi-C, Iso-Seq, and Metagenome Assembled Genome (MAG) analysis—the company achieves a state-of-the-art, comprehensive, and efficient genome analysis.
PtBio also offers customised systems tailored to the unique requirements of different projects by maximising data quality and analytical efficiency. This flexible approach enhances the likelihood of uncovering critical biological insights often missed in standard analyses, delivering new value to clients’ research and product development.
Cutting-Edge Genome Editing
PtBio is also known for its advanced genome-editing tool, Platinum TALEN, developed by its Chief Technical Officer, Taku Yamamoto, who serves as Vice President of the Japan Society for Genome Editing. Yamamoto leads national projects such as OPERA and COI-NEXT.
The collaboration between Hiroshima University and PtBio yields products and services that address both academic and industrial needs, providing solutions with reliability and practicality. It is a culmination of the university’s and company’s facilities and expertise.
PtBio’s core technology, FirmCut Platinum TALEN, features superior
DNA binding due to periodic repeats, achieving low off-target effects and high safety. With a cleavage efficiency that surpasses conventional FokI-based systems, it enables more precise and efficient genome editing. Platinum TALEN’s strong binding ability has demonstrated successful genome editing across a variety of organisms and cell types, showcasing its broad application potential.
Additionally, the company is developing next-generation tools, such as ZF-ND1 for drug discovery applications, continuing its commitment to innovation.
Industrial Applications of PtBio’s Technology
PtBio’s technology is optimised for diverse needs, from basic research to large-scale industrial applications. Its flexible licensing system, designed to be affordable and compliant with CRISPR/TALEN patents, reduces legal risks and facilitates use in various fields, including biopharmaceutical development, agriculture and food industries, environmental biotechnology, and regenerative medicine.
Several companies have successfully adopted PtBio’s technology across different sectors:
Sustainable Food Production
PtBio collaborates with Yanmar Holdings and Hiroshima University to develop a sustainable food production system using advanced metagenomic analysis. This project focuses on optimising microbial communities to enhance resource recovery from organic waste. By integrating sequencing and bioinformatics, the approach improves efficiency in converting organic materials from waste into useful products. The goal is to reduce environmental impact, produce high-quality organic fertilisers, and support sustainable agriculture by establishing an effective, science-backed recycling system.
Optimising Sewage Treatment
The “Metagenomic Analysis for Sewage Treatment” project, in collaboration with Hitachi Zosen, aims to optimise sewage treatment through metagenomic analysis. By profiling microbial communities with high precision, this approach enhances nitrogen removal efficiency, reduces electricity usage, and cuts CO₂ emissions. The initiative employs advanced sequencing and predictive modelling to adapt to seasonal changes, with potential applications for scaling the “Hiroshima City Model” nationwide and globally.
Carbon Recycling
PtBio and Tsuneishi have launched a joint research project to utilise microalgae Nannochloropsis to capture and recycle CO₂ into valuable substances. The research focuses on optimising lab-scale cultivation conditions for potential outdoor applications, using genetic expression analysis. This initiative supports a carbon recycling society by developing innovative CO₂ utilisation solutions.
Allergen-Free Egg Development
PtBio’s cutting-edge genome editing technology targets and removes the OVM gene responsible for triggering allergic reactions, creating the world’s first allergen-free egg that retains the taste and functionality of real eggs. The company’s patented, precision approach ensures a natural solution for egg allergy sufferers without compromising quality. Rigorous testing, including clinical trials, has confirmed the product’s safety. A recent trial with 17 individuals with egg allergies showed no adverse reactions when consuming the powdered egg product under medical supervision.
A Future Built on Innovation
These examples demonstrate PtBio’s ability to offer customised solutions tailored to each project’s unique requirements and goals. Supported by an experienced team, clients receive comprehensive support in technology integration, experimental design, data analysis, and interpretation, ensuring success across the entire workflow.
PtBio is actively seeking collaboration opportunities in research and development. For those looking to enhance their research and business with cutting-edge biotechnology, PtBio offers the tools and expertise to drive innovation towards a sustainable future.
